Trenibotulinumtoxine

Summary

Trenibotulinumtoxine (CHEMBL4594539) is a phase-3 clinical-stage protein; indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 1 condition
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594539
Name	Trenibotulinumtoxine
Type	Protein
Max phase	3

Also known as: AGN-151586, Bontoxilysin-e, Botulinum neurotoxin type e, Botulinum toxin type e, BoNT/E, Eb-001, EB-001, Trenibotulinumtoxine, TRENIBOTULINUMTOXINE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE3	4
PHASE2	4
PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05248867	PHASE3	COMPLETED	A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
NCT05248880	PHASE3	COMPLETED	A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines
NCT05248893	PHASE3	COMPLETED	A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
NCT06308198	PHASE3	COMPLETED	A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines
NCT02939326	PHASE2	COMPLETED	Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines
NCT03193593	PHASE2	COMPLETED	Study to Evaluate EB-001 in Reducing Musculoskeletal Pain
NCT03346902	PHASE2	COMPLETED	Study of EB-001 in Facial Scar Reduction
NCT04096326	PHASE2	COMPLETED	AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
NCT05496335	PHASE1	COMPLETED	A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines
NCT06151561	PHASE1	COMPLETED	Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines
NCT06834789	PHASE1	COMPLETED	A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).